Literature DB >> 17392732

The PET radioligand [11C]MePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain.

Fumihiko Yasuno1, Amira K Brown, Sami S Zoghbi, Joseph H Krushinski, Eyassu Chernet, Johannes Tauscher, John M Schaus, Lee A Phebus, Amy K Chesterfield, Christian C Felder, Robert L Gladding, Jinsoo Hong, Christer Halldin, Victor W Pike, Robert B Innis.   

Abstract

The cannabinoid CB(1) receptor is one of the most abundant G protein-coupled receptors in the brain and is a promising target of therapeutic drug development. Success of drug development for neuropsychiatric indications is significantly enhanced with the ability to directly measure spatial and temporal binding of compounds to receptors in central compartments. We assessed the utility of a new positron emission tomography (PET) radioligand to image CB(1) receptors in monkey brain. [(11)C]MePPEP ((3R,5R)-5-(3-methoxy-phenyl)-3-((R)-1-phenyl-ethylamino)-1-(4-trifluoromethyl-phenyl)-pyrrolidin-2-one) has high CB(1) affinity (K(b)=0.574+/-0.207 nM) but also moderately high lipophilicity (measured LogD(7.4)=4.8). After intravenous injection of [(11)C]MePPEP, brain activity reached high levels of almost 600% standardized uptake value (SUV) within 10-20 min. The regional uptake was consistent with the distribution of CB(1) receptors, with high radioactivity in striatum and cerebellum and low in thalamus and pons. Injection of pharmacological doses of CB(1)-selective agents confirmed that the tracer doses of [(11)C]MePPEP reversibly labeled CB(1) receptors. Preblockade or displacement with two CB(1) selective agents (ISPB; (4-(3-cyclopentyl-indole-1-sulfonyl)-N-(tetrahydro-pyran-4-ylmethyl)-benzamide) and rimonabant) showed that the majority (>89%) of brain uptake in regions with high receptor densities was specific and reversibly bound to CB(1) receptors in the high binding regions. [(11)C]MePPEP was rapidly removed from arterial plasma. Regional brain uptake could be quantified as distribution volume relative to the concentration of parent radiotracer in plasma. The P-glycoprotein (P-gp) inhibitor DCPQ ((R)-4-[(1a,6,10b)-1,1-dichloro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]-[(5-quinolinyloxy)methyl]-1-piperazineethanol) did not significantly increase brain uptake of [(11)C]MePPEP, suggesting it is not a substrate for this efflux transporter at the blood-brain barrier. [(11)C]MePPEP is a radioligand with high brain uptake, high specific signal to CB(1) receptors, and adequately fast washout from brain that allows quantification with (11)C (half-life=20 min). These promising results in monkey justify studying this radioligand in human subjects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17392732     DOI: 10.1038/sj.npp.1301402

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  37 in total

1.  Radiosynthesis and evaluation of an (18)F-labeled positron emission tomography (PET) radioligand for brain histamine subtype-3 receptors based on a nonimidazole 2-aminoethylbenzofuran chemotype.

Authors:  Xiaofeng Bao; Shuiyu Lu; Jeih-San Liow; Sami S Zoghbi; Kimberly J Jenko; David T Clark; Robert L Gladding; Robert B Innis; Victor W Pike
Journal:  J Med Chem       Date:  2012-02-16       Impact factor: 7.446

Review 2.  In vivo imaging of the endocannabinoid system: a novel window to a central modulatory mechanism in humans.

Authors:  Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11       Impact factor: 9.236

3.  Evaluation of a PET Radioligand to Image O-GlcNAcase in Brain and Periphery of Rhesus Monkey and Knock-Out Mouse.

Authors:  Soumen Paul; Mohammad B Haskali; Jeih-San Liow; Sami S Zoghbi; Vanessa N Barth; Marcy Comly Kolodrubetz; Michelle R Bond; Cheryl L Morse; Robert L Gladding; Michael P Frankland; Nancy Kant; Lawrence Slieker; Sergey Shcherbinin; Hugh N Nuthall; Paolo Zanotti-Fregonara; John A Hanover; Cynthia Jesudason; Victor W Pike; Robert B Innis
Journal:  J Nucl Med       Date:  2018-09-13       Impact factor: 10.057

4.  Synthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging.

Authors:  Sean R Donohue; Joseph H Krushinski; Victor W Pike; Eyassu Chernet; Lee Phebus; Amy K Chesterfield; Christian C Felder; Christer Halldin; John M Schaus
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

5.  Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): development of ligands with optimized lipophilicity and binding affinity.

Authors:  Hong Fan; Evangelia Kotsikorou; Alexander F Hoffman; Hayden T Ravert; Daniel Holt; Dow P Hurst; Carl R Lupica; Patricia H Reggio; Robert F Dannals; Andrew G Horti
Journal:  Eur J Med Chem       Date:  2008-04-18       Impact factor: 6.514

6.  Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using (18)F-labeled inverse agonist radioligands.

Authors:  Garth E Terry; Jussi Hirvonen; Jeih-San Liow; Sami S Zoghbi; Robert Gladding; Johannes T Tauscher; John M Schaus; Lee Phebus; Christian C Felder; Cheryl L Morse; Sean R Donohue; Victor W Pike; Christer Halldin; Robert B Innis
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

7.  Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents.

Authors:  Garth Terry; Jeih-San Liow; Eyassu Chernet; Sami S Zoghbi; Lee Phebus; Christian C Felder; Johannes Tauscher; John M Schaus; Victor W Pike; Christer Halldin; Robert B Innis
Journal:  Neuroimage       Date:  2008-03-18       Impact factor: 6.556

8.  Development and characterization of a promising fluorine-18 labelled radiopharmaceutical for in vivo imaging of fatty acid amide hydrolase.

Authors:  Oleg Sadovski; Justin W Hicks; Jun Parkes; Roger Raymond; José Nobrega; Sylvain Houle; Mariateresa Cipriano; Christopher J Fowler; Neil Vasdev; Alan A Wilson
Journal:  Bioorg Med Chem       Date:  2013-05-07       Impact factor: 3.641

9.  Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier.

Authors:  Rong Zhao; Thomas J Raub; Geri A Sawada; Steven C Kasper; James A Bacon; Arlene S Bridges; Gary M Pollack
Journal:  Drug Metab Dispos       Date:  2009-03-09       Impact factor: 3.922

10.  Synthesis and in vitro autoradiographic evaluation of a novel high-affinity radioiodinated ligand for imaging brain cannabinoid subtype-1 receptors.

Authors:  Sean R Donohue; Katarina Varnäs; Zhisheng Jia; Balázs Gulyás; Victor W Pike; Christer Halldin
Journal:  Bioorg Med Chem Lett       Date:  2009-09-03       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.